Online inquiry

IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12423MR)

This product GTTS-WQ12423MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNG gene. The antibody can be applied in Hemophagocytic lymphohistiocytosis (HLH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000619.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3458
UniProt ID P01579
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12423MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11616MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ10173MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ14972MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SHR-1314
GTTS-WQ12157MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-009
GTTS-WQ7594MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ10376MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ2340MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AME-133v
GTTS-WQ7794MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GS-HIV
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.